Pfizer Seeks Approval for Lyme Disease Vaccine Despite Trial Setback

First Lyme Vaccine in Over Two Decades Shows Promise

Pfizer and its partner Valneva are with regulatory approval for their Lyme disease vaccine despite a technical failure in their late-stage clinical trial. The vaccine candidate demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above , marking what could be the first human vaccine against the tick-borne illness approved in over 20 years.

The Phase 3 VALOR trial involved approximately 9,400 healthy participants from areas with endemic levels of Lyme disease, such as Europe, Canada, and the United States . While the vaccine showed strong protection rates, fewer cases than expected during the trial resulted in the companies failing to meet pre-determined statistical criterion in the first round of analysis . However, in a second analysis, the vaccine demonstrated clinically meaningful efficacy, with the lower bound of the 95 percent confidence interval at 21.7 percent .

This represents a significant milestone for a disease that affects hundreds of thousands of Americans annually. Recent estimates suggest that approximately 476,000 people may be diagnosed and treated for Lyme disease each year in the United States , though only 89,000 cases of Lyme disease were reported to CDC by state health departments in 2023 .

A Long-Awaited Medical Breakthrough

The last human Lyme disease vaccine, LYMErix, debuted in 1998 but was pulled after four years due to low sales driven by concerns about potentially adverse effects . That vaccine was said to reduce new infections in vaccinated adults by nearly 80 percent , but public fears about safety effectively killed demand and discouraged further development for decades.

Pfizer's current vaccine candidate works through an innovative mechanism. As the tick feeds on the vaccinated person, vaccine-induced antibodies are ingested by the tick as part of its blood meal, binding to bacteria inside the tick and preventing transmission to the human host . The vaccination series involves three shots in the first year, then a booster dose the following year .

The companies reported no safety concerns during the trial, and partner Valneva has said the Lyme disease shot could reach annual peak sales of more than $1 billion . The vaccine targets six different strains of the bacteria that cause Lyme disease, offering broader protection than previous attempts.

Regulatory Challenges Ahead

Despite the promising efficacy data, Pfizer faces potential scrutiny from regulators. with a shot that technically failed a clinical trial under an administration that has preached stricter scrutiny for vaccines may prove risky for Pfizer . The companies had to overcome significant obstacles during development, including dropping about half of the participants in the Phase 3 trial because of quality concerns with third-party clinical trial site operator Care Access, reducing enrollment from about 18,000 to about 9,400 .

The statistical hurdle that tripped up the trial is significant. A commonly used benchmark for a vaccine to be approved requires trials to show a reduction in the risk of disease by at least 20 percent . While the vaccine ultimately cleared this bar in secondary analysis, regulators will need to weigh whether the evidence is sufficient for approval.

Lyme disease symptoms range from the characteristic expanding rash to severe arthritis, neurological issues and cardiac complications if left untreated . The disease is particularly prevalent in the Northeast, mid-Atlantic, and upper Midwest regions, where outdoor activities put millions at risk during tick season.

Hope for High-Risk Populations

If approved, the vaccine could provide crucial protection for people frequently exposed to tick habitats. The vaccine could address a significant unmet medical need, particularly for populations frequently exposed to tick habitats, such as outdoor workers and recreational hikers . The timing is critical, as the range of Lyme disease cases in the United States has expanded significantly since 1995 .

The vaccine's broad age range, covering individuals five years and older, could offer protection for families living in or visiting endemic areas. With climate change potentially expanding tick habitats and extending tick seasons, a preventive vaccine represents a valuable tool in public health's arsenal against this growing threat.

Pfizer plans to submit the vaccine for regulatory review in the coming months. If successful, it would end a decades-long gap in Lyme disease prevention and provide the first new option for protecting against America's most common vector-borne illness.